Literature DB >> 15705644

Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.

Judith N Steenbergen1, Jeff Alder, Grace M Thorne, Francis P Tally.   

Abstract

Infections caused by drug-resistant pathogens are on the rise. Daptomycin, a cyclic lipopeptide with activity against most Gram-positive pathogens, including vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus, is a newly US-FDA approved antimicrobial for complicated skin and skin structure infections (cSSSI). Daptomycin has a unique mechanism of action that results in destruction of the membrane potential. The rapid bactericidal activity of daptomycin makes it an attractive antibiotic for serious Gram-positive infections.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15705644     DOI： 10.1093/jac/dkh546

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  136 in total

1.  Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.

Authors:  C Garrigós; O Murillo; G Euba; R Verdaguer; F Tubau; C Cabellos; J Cabo; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Pharmacokinetic-pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries.

Authors:  A Canut; A Isla; C Betriu; A R Gascón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-02-28       Impact factor: 3.267

3.  Ubiquitous detection of gram-positive bacteria with bioorthogonal magnetofluorescent nanoparticles.

Authors:  Hyun Jung Chung; Thomas Reiner; Ghyslain Budin; Changwook Min; Monty Liong; David Issadore; Hakho Lee; Ralph Weissleder
Journal:  ACS Nano       Date:  2011-10-10       Impact factor: 15.881

4.  Diversity of monomers in nonribosomal peptides: towards the prediction of origin and biological activity.

Authors:  Ségolène Caboche; Valérie Leclère; Maude Pupin; Gregory Kucherov; Philippe Jacques
Journal:  J Bacteriol       Date:  2010-08-06       Impact factor: 3.490

5.  Diminished macrophage inflammatory response to Staphylococcus aureus isolates exposed to daptomycin versus vancomycin or oxacillin.

Authors:  B Keith English; Erik M Maryniw; Ajay J Talati; Elizabeth A Meals
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

6.  Ultrashort antibacterial and antifungal lipopeptides.

Authors:  Arik Makovitzki; Dorit Avrahami; Yechiel Shai
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-12       Impact factor: 11.205

7.  Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology.

Authors:  Kim Credito; Gengrong Lin; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

8.  New drugs to treat skin and soft tissue infections.

Authors:  Gary E Stein
Journal:  Curr Infect Dis Rep       Date:  2007-09       Impact factor: 3.725

9.  Correlation of cell membrane lipid profiles with daptomycin resistance in methicillin-resistant Staphylococcus aureus.

Authors:  Nagendra N Mishra; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

10.  Inactivation of the phosphoglucomutase gene pgm in Paenibacillus polymyxa leads to overproduction of fusaricidin.

Authors:  Ha-Rim Kim; Soo-Young Park; Seong-Bin Kim; Haeyoung Jeong; Soo-Keun Choi; Seung-Hwan Park
Journal:  J Ind Microbiol Biotechnol       Date:  2014-06-18       Impact factor: 3.346
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.